Oss-Q has received SEK 13.7mn through a rights issue and will initiate a clinical trial with OssDsign Cranio PSI, its implant for skull reconstruction. In connection with these advances, the company has changed its name to OssDsign. Karolinska Development invested SEK 6.8mn in the rights issue, increasing its ownership in OssDsign from 16 to 26%.
In addition to clinical outcome, the clinical study of OssDsign Cranio PSI will evaluate quality of life and health economics in patients requiring skull reconstruction. The first patients in the study have recently been treated at the Karolinska University Hospital in Stockholm, Sweden. The study is being conducted in patients for whom previous treatments with conventional skull implants have failed. The results so far suggest that this implant could be an important new option for this patient category, particularly if the skull injuries are severe.
According to OssDsign, the launch of OssDsign Cranio PSI will provide a valuable platform for further development of applications in skull surgery and in other orthopaedic areas, such as fracture healing.